Catalyst Pharmaceuticals (CPRX) EBT (2010 - 2026)

Catalyst Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $84.2 million for Q1 2026.

• Quarterly EBT rose 18.16% year-over-year to $84.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $296.5 million (up 14.7% YoY) and the FY2025 annual result came in at $283.5 million, up 31.1% from the prior year.
• EBT was $84.2 million for Q1 2026 at Catalyst Pharmaceuticals, up from $71.9 million in the prior quarter.
• Across five years, EBT topped out at $84.2 million in Q1 2026 and bottomed at -$38.0 million in Q3 2023.
• A 5-year average of $46.1 million and a median of $48.5 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT slumped 246.2% — and 2024, when it jumped 250.46%.
• Catalyst Pharmaceuticals' EBT stood at $33.0 million in 2022, then soared by 41.5% to $46.7 million in 2023, then jumped by 58.82% to $74.2 million in 2024, then dropped by 3.07% to $71.9 million in 2025, then increased by 17.15% to $84.2 million in 2026.
• Business Quant data shows CPRX's EBT at $84.2 million in Q1 2026, $71.9 million in Q4 2025, and $71.0 million in Q3 2025.